Nordic Nanovector ASA (OSE: NANO), a company committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care, has reported its financial results for 2019, on Thursday.
Revenues for the full year 2019 were NOK0.0m, the same as last year.
The company reported total operating expenses for 2019 at NOK440.4m compared to NOK340m in 2018.
The firm posted comprehensive loss for 2019 at NOK433.3m compared to NOK336.8m in 2018.
Jan H Egberts, MD, chairman of Nordic Nanovector, commented: 'We currently have 47 patients enrolled in our pivotal PARADIGME Phase 2b trial evaluating Betalutin. The company will under its new management look into the current strategy and operational trial initiatives. We still aim to complete the patient enrolment in PARADIGME in the second half of 2020. The encouraging efficacy and safety profile demonstrated in the first part of the LYMRIT 37-01 Phase 1/2 trial with a single administration of Betalutin give the Board and management confidence in its potential to become an important option for patients with non-Hodgkin's lymphoma (NHL).'
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study
Precision Epigenomics partners with TruDiagnostic
Modalis partners with Ginkgo Bioworks
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Algiax Pharmaceuticals reveals update on chronic neuropathic pain study